Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortex

GLIA

Volumn 63, Issue 1, 2015, Pages 104-117

  El Etr, Martine ^a   Rame, Marion ^a   Boucher, Celine ^a   Ghoumari, Abdel M ^a   Kumar, Narender ^b   Liere, Philippe ^a   Pianos, Antoine ^a   Schumacher, Michael ^a   Sitruk Ware, Regine ^b  

^a Universite Paris Sud   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cuprizone; Oligodendrocytes; Progesterone receptor; Progestogens; Remyelination

Indexed keywords

CUPRIZONE; ELCOMETRINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN; MYELIN BASIC PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEOLIPID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN CORTEX LESION; CELL ACTIVATION; CELL DENSITY; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATING DISEASE; DEMYELINATION; DRUG BLOOD LEVEL; FEMALE; GRAY MATTER; MICROGLIA; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; SILICONE PROSTHESIS; TREATMENT DURATION; WHITE MATTER; ANIMAL; C57BL MOUSE; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; MULTIPLE SCLEROSIS; MYELIN SHEATH; PATHOLOGY; STEM CELL;

ANIMALS; CEREBRAL CORTEX; CORPUS CALLOSUM; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FEMALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; OLIGODENDROGLIA; PROGESTERONE; STEM CELLS;

EID: 84911988512     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22736     Document Type: Article

References (70)

1. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C. 2009. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:807-814.
2. Armstrong RC, Le TQ, Flint NC, Vana AC, Zhou YX. 2006. Endogenous cell repair of chronic demyelination. J Neuropathol Exp Neurol 65:245-256.
3. Bastida CM, Tejada F, Cremades A, Penafiel R. 2002. The preovulatory rise of ovarian ornithine decarboxylase is required for progesterone secretion by the corpus luteum. Biochem Biophys Res Commun 293:106-111.
4. Blaustein JD, Turcotte JC. 1989. Estrogen receptor-immunostaining of neuronal cytoplasmic processes as well as cell nuclei in guinea pig brain. Brain Res 495:75-82.
5. Calabrese M, Filippi M, Gallo P. 2010. Cortical lesions in multiple sclerosis. Nat Rev Neurol 6:438-444.
6. Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, Rinaldi F, Perini P, Gallo P. 2012. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135:2952-2961.
7. De Nicola AF, Labombarda F, Gonzalez Deniselle MC, Gonzalez SL, Garay L, Meyer M, Gargiulo G, Guennoun R, Schumacher M. 2009. Progesterone neuroprotection in traumatic CNS injury. Front Neuroendocrinol 30:173-187.
8. Deboy CA, Zhang J, Dike S, Shats I, Jones M, Reich DS, Mori S, Nguyen T, Rothstein B, Miller RH, Griffin JT, Kerr DA, Calabresi PA. 2007. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain 130:2199-2210.
9. Franklin JL, Johnson EM. 1992. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci 15:501-508.
10. Franklin RJ, FFrench-Constant C, Edgar JM, Smith KJ. 2012. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8:624-634.
11. Fraser IS, Weisberg E, Kumar N, Kumar S, Humberstone AJ, McCrossin L, Shaw D, Tsong YY, Sitruk-Ware R. 2007. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 76:432-438.
12. Friese MA, Schattling B, Fugger L. 2014. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10:225-238.
13. Garay L, Deniselle MC, Lima A, Roig P, De Nicola AF. 2007. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol 107:228-237.
14. Garay L, Tungler V, Deniselle MC, Lima A, Roig P, De Nicola AF. 2011. Progesterone attenuates demyelination and microglial reaction in the lysolecithin-injured spinal cord. Neuroscience 192:588-597.
15. Geldenhuys WJ, Van der Schyf CJ. 2013. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 8:115-129.
16. Geurts JJ, Calabrese M, Fisher E, Rudick RA. 2012. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 11:1082-1092.
17. Ghoumari AM, Ibanez C, el-Etr M, Leclerc P, Eychenne B, Malley BW, Baulieu EE, Schumacher M. 2003. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 86:848-859.
18. Giatti S, Caruso D, Boraso M, Abbiati F, Ballarini E, Calabrese D, Pesaresi M, Rigolio R, Santos-Galindo M, Viviani B, Cavaletti G, Garcia-Segura LM, Melcangi RC. 2012. Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. J Neuroendocrinol 24:851-861.
19. Gibson CL, Gray LJ, Bath PM, Murphy SP. 2008. Progesterone for the treatment of experimental brain injury: a systematic review. Brain 131:318-328.
20. Gofflot F, Chartoire N, Vasseur L, Heikkinen S, Dembele D, Le MJ, Auwerx J. 2007. Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 131:405-418.
21. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. 2008. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 28:14189-14201.
22. Hussain R, El-Etr M, Gaci O, Rakotomamonjy J, Macklin WB, Kumar N, Sitruk-Ware R, Schumacher M, Ghoumari AM. 2011. Progesterone and nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology 152:3820-3831.
23. Hussain R, Ghoumari AM, Bielecki B, Steibel J, Boehm N, Liere P, Macklin WB, Kumar N, Habert R, Mhaouty-Kodja S, Tronche F, Sitruk-Ware R, Schumacher M, Ghandour MS. 2013. The neural androgen receptor: a therapeutic target for myelin repair in chronic de B, myelination. Brain 136:132-146.
24. Ibanez C, Shields SA, El-Etr M, Baulieu EE, Schumacher M, Franklin RJ. 2004. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol Appl Neurobiol 30:80-89.
25. Ismail PM, Li J, DeMayo FJ, O'Malley BW, Lydon JP. 2002. A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol 16:2475-2489.
26. Jung-Testas I, Renoir JM, Gasc JM, Baulieu EE. 1991. Estrogen-inducible progesterone receptor in primary cultures of rat glial cells. Exp Cell Res 193:12-19.
27. Khalaj AJ, Yoon J, Nakai J, Winchester Z, Moore SM, Yoo T, Martinez-Torres L, Kumar S, Itoh N, Tiwari-Woodruff SK. 2013. Estrogen receptor (ER) beta expression in oligodendrocytes is required for attenuation of clinical disease by an ERbeta ligand. Proc Natl Acad Sci USA 110:19125-19130.
28. Kieseier BC, Stüve O. 2011. A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol 7:255-262.
29. Kipp M, Clarner T, Dang J, Copray S, Beyer C. 2009. The cuprizone animal model: new insights into an old story. Acta Neuropathol 118:723-736.
30. Koenig HL, Schumacher M, Ferzaz B, Do Thi AN, Ressouches A, Guennoun R, Jung-Testas I, Robel P, Akwa Y, Baulieu EE. 1995. Progesterone synthesis and myelin formation by Schwann cells. Science 268:1500-1503.
31. Kotter MR, Zhao C, van Rooijen N, Franklin RJ. 2005. Macrophage depletion induced impairment of experimental CNS remyelination associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 18:166-175.
32. Kumar N, Koide SS, Tsong Y, Sundaram K. 2000. Nestorone: a progestin with a unique pharmacological profile. Steroids 65:629-636.
33. Labombarda F, Gonzalez SL, Lima A, Roig P, Guennoun R, Schumacher M, De Nicola AF. 2009. Effects of progesterone on oligodendrocyte progenitors, oligodendrocyte transcription factors, and myelin proteins following spinal cord injury. Glia 57:884-897.
34. Ligon KL, Fancy SP, Franklin RJ, Rowitch DH. 2006. Olig gene function in CNS development and disease. Glia 54:1-10.
35. Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M. 2009. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453:120-125.
36. Liu L, Zhao L, She H, Chen S, Wang JM, Wong C, McClure K, Sitruk-Ware R, Brinton RD. 2010.Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology 151:5782-5794.
37. Liu A, Margaill I, Zhang S, Labombarda F, Coqueran B, Delespierre B, Liere P, Marchand-Leroux C, O'Malley BW, Lydon JP, De Nicola AF, Sitruk-Ware R, Mattern C, Plotkine M, Schumacher M, Guennoun R. 2012. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology 153:3747-3757.
38. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Jr., Shyamala G, Conneely OM, O'Malley BW. 1995. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266-2278.
39. Maire CL, Wegener A, Kerninon C, Nait OB. 2010. Gain-of-function of Olig transcription factors enhances oligodendrogenesis and myelination. Stem Cells 28:1611-1622.
40. Mani SK, Blaustein JD, O'Malley BW. 1997. Progesterone receptor function from a behavioral perspective. Horm Behav 31:244-255.
41. Martino G, Franklin RJ, Baron Van EA, Kerr DA. 2010. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 6:247-255.
42. Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE, Matsushima GK. 2004. Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol 164:1673-1682.
43. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.
44. Melcangi RC, Panzica GC. 2014. Allopregnanolone: state of the art. Prog Neurobiol 113:1-5.
45. Moore CS, Abdullah SL, Brown A, Arulpraqasam A, Crocker SJ. 2011. How factors secreted from astrocytes impact myelin repair. J Neurosci Res 89:13-21.
46. Nave KA, Trapp BD. 2008. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 31:535-561.
47. Parsons B, Rainbow TC, MacLusky NJ, McEwen BS. 1982. Progestin receptor levels in rat hypothalamic and limbic nuclei. J Neurosci 2:1446-1452.
48. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP, Teuscher C, Vandenbark AA, Offner H. 2003. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol 163:1599-1605.
49. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. 2002. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215-223.
50. Popovich PG, Longbrake EE. 2008. Can the immune system be harnessed to repair the CNS? Nat Rev Neurosci 9:481-493.
51. Sakamoto H, Ukena K, Tsutsui K. 2001. Effects of progesterone synthesized de novo in the developing Purkinje cell on its dendritic growth and synaptogenesis. J Neurosci 21:6221-6232.
52. Sayeed I, Stein DG. 2009. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog Brain Res 175:219-237.
53. Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF, Guennoun R. 2014. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol 113:6-39.
54. Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS, Bulloch K. 2008. Steroid hormone receptor expression and function in microglia. Glia 56:659-674.
55. Sitruk-Ware R, Nath A. 2010. The use of newer progestins for contraception. Contraception 82:410-417.
56. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, Trebst C, Stangel M. 2008. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172:1053-1061.
57. Skripuletz T, Miller E, Moharregh-Khiabani D, Blank A, Pul R, Gudi V, Trebst C, Stangel M. 2010. Beneficial effects of minocycline on cuprizone induced cortical demyelination. Neurochem Res 35:1422-1433.
58. Spence RD, Hamby ME, Umeda E, Itoh N, Du S, Wisdom AJ, Cao Y, Bondar G, Lam J, Ao Y, Sandoval F, Suriany S, Sofroniew MV, Voskuhl RR. 2011. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci USA 108:8867-8872.
59. Stein DG. 2011. Is progesterone a worthy candidate as a novel therapy for traumatic brain injury? Dialogues Clin Neurosci 13:352-359.
60. Taylor LC, Gilmore W, Ting JP, Matsushima GK. 2010. Cuprizone induces similar demyelination in male and female C57BL/6 mice and results in disruption of the estrous cycle. J Neurosci Res 88:391-402.
61. Van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S. 2012. In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets 11:570-588.
62. Wang C, Dehghani B, Li Y, Kaler LJ, Vandenbark AA, Offner H. 2009. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 126:329-335.
63. Warembourg M, Jolivet A, Milgrom E. 1989. Immunohistochemical evidence of the presence of estrogen and progesterone receptors in the same neurons of the guinea pig hypothalamus and preoptic area. Brain Res 480:1-15.
64. Waters EM, Torres-Reveron A, McEwen BS, Milner TA. 2008. Ultrastructural localization of extranuclear progestin receptors in the rat hippocampal formation. J Comp Neurol 511:34-46.
65. Wood GA, Fata JE, Watson KL, Khokha R. 2007. Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction 133:1035-1044.
66. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG. 2007. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 49:391-402.
67. Xiao G, Wei J, Yan W, Wang W, Lu Z. 2008. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 12:R61.
68. Yates MA, Li Y, Chlebeck P, Proctor T, Vandenbark AA, Offner H. 2010. Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis. J Neuroimmunol 220:136-139.
69. Youdim MB, Buccafusco JJ. 2005. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26:27-35.
70. Yu HJ, Fei J, Chen XS, Cai QY, Liu HL, Liu GD, Yao ZX. 2010. Progesterone attenuates neurological behavioral deficits of experimental autoimmune encephalomyelitis through remyelination with nucleus-sublocalized Olig1 protein. Neurosci Lett 476:42-45.